News
China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback